229975-97-7
229975-97-7 structure
- Name: Atazanavir sulfate
- Chemical Name: atazanavir sulfate
- CAS Number: 229975-97-7
- Molecular Formula: C38H54N6O11S
- Molecular Weight: 802.934
- Catalog: API Antibiotics Other antibiotics
- Create Date: 2018-08-24 11:44:48
- Modify Date: 2026-07-05 20:20:23
-
Atazanavir sulfate is a sulfate salt form of atazanavir that is an highly potent HIV-1 protease inhibitor.Target: HIV-1 protease inhibitorAtazanavir sulfate is a sulfate salt form of atazanavir that is an highly potent HIV-1 protease inhibitor. It has a pharmacokinetic profile that supports once-daily dosing and has demonstrated a unique resistance profile and superior virologic potency compared with other antiretrovirals in vitro. In subjects with HIV, atazanavir (400 mg once daily) produced rapid and sustained improvements in viral load and CD4 counts in both antiretroviral-naive as well as previously treated patients when used in combination with dual nucleoside reverse transcriptase inhibitor (NRTI) treatment [1].After intravenous (iv), oral (po) and intraportal (ip) administration of ATV at a dosage of 7 mg/kg, AUCs in HL rats were 12.41, 5.24 and 8.89 microg/mLh, respectively, and were significantly higher than those in control rats (4.09, 1.70 and 3.38 microg/mLh). Despite the decrease of distribution volume (Vd(ss)), the terminal half-life (t(1/2)) in HL tended to be shorter than in control, and hepatic distribution of ATV in HL rats was 4.8-fold increases. These results suggested that the uptake of ATV into liver might counteract the decrease of Vd(ss). On the other hand, there was no significant difference in bioavailability, and the lymphatic transport to AUC showed no statistical change. In conclusion, although the protein binding rate and AUC were significantly increased, the pharmacokinetics of ATV might be tolerated in HL [2].Clinical indications: HIV-1 infection Toxicity: torsades de pointes
| Name | atazanavir sulfate |
|---|---|
| Synonyms |
Atazanavir sulfate (BMS-232632-05)
Zrivada Zrivada {Sulfate} methyl [(1S,4S,5S,10S)-4-benzyl-1,10-di-tert-butyl-5-hydroxy-2,9,12-trioxo-7-(4-pyridin-2-ylbenzyl)-13-oxa-3,7,8,11-tetraazatetradec-1-yl]carbamate sulfate (salt) BMS-232632-05 {Sulfate} Methyl {(5S,10S,11S,14S)-11-benzyl-10-hydroxy-15,15-dimethyl-5-(2-methyl-2-propanyl)-3,6,13-trioxo-8-[4-(2-pyridinyl)benzyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl}carbamate sulfate (1:1) (non-preferred name) Butanoic acid, 2-[(methoxycarbonyl)amino]-3,3-dimethyl-, 2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethyl-1-oxobutyl]amino]-4-phenylbutyl]-2-[[4-(2-pyridinyl)phenyl]methyl]hydrazide, (2S)-, sulfate (1:1) (salt) Atazanavir (BMS-232632) sulfate ATAZANAVIR SULFATE (NON-STERILE DRUG SUBSTANCE) Dimethyl (3S,8S,9S,12S)-9-benzyl-3,12,di-tert-butyl-8-hydroxy-4,11-dioxo-6-(p-2-pyridylbenzyl)-2,5,6,10,13-pentaazatetradecanedioate sulfate N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycbonylamino)-3,3-dimethyl-1-oxobutyl]amino]-4-phenylbutyl]-2-[(4-phenylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]cbamic acid methyl Atazanavir Bisulfate Salt BMS 232632 sulfate Atazanavir sulfateQ: What is Atazanavir sulfate Q: What is the CAS Number of Atazanavir sulfate Q: What is the storage condition of Atazanavir sulfate Q: What e the applications of Atazanavir sulfate Atazanavir sulfate HIV protease inhibitors Atazanavir Sulfate (Latazanavir, Zrivada, Reyataz, BMS232632) [(1S,4S,5S,10S)-4-benzyl-1,10-bis(1,1-diméthyléthyl)-5-hydroxy-2,9,12-trioxo-7-(4-pyridin-2-ylbenzyl)-13-oxa-3,7,8,11-tétraazatétradéc-1-yl]carbamate de méthyle sulfate (salt) Methyl {(5S,10S,11S,14S)-11-benzyl-10-hydroxy-15,15-dimethyl-5-(2-methyl-2-propanyl)-3,6,13-trioxo-8-[4-(2-pyridinyl)benzyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl}cbamate ((5S,6S)-5-hydroxy-1,8-dioxo-6-(phenyl methyl)-3-[[4-(2- pyridinyl)phenyl]methyl] -2,3,7 triaza octane dioic acid tertiy butyl ester) Atazanavir Sulfate ATAZANAVIR SULPHATE [DRUG SUBSTANCE (NON-STERILE)] Aids-060276 Atazanavir (sulfate) ATAZANAVIR SULFATE (BMS-232632 SULFATE) BMS 232632 SULFATE;BMS-232632 SULFATE;BMS232632 SULFATE Azanavir sulfate BMS232632 sulfate Methyl N-[(1S)-1-{[(2S,3S)-3-hydroxy-4-[(2S)-2-[(Methoxycbonyl)amino]-3,3-diMethyl-N'-{[4-(pyridin-2-yl)phenyl]Methyl}butanehydrazido]-1-phenylbutan-2-yl]cbaMoyl}-2,2-diMethylpropyl]cbaMate 2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester, (3S,8S,9S,12S)-, sulfate (1:1) (salt) Atazanavir sulfate //BP BMS-232632-05 Cgp Aids060276 Atazanavir sulfate, 10 mM in DMSO (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioic acid 1,14-dimethyl ester, sulfate (1:1) Methyl N-[(2S)-1-[[(2S,3S)-3-hydroxy-4-[[[(2S)-2-(methoxycbonylamino)-3,3-dimethylbutanoyl]amino]-[(4-pyridin-2-ylphenyl)methyl]amino]-1-phenylbutan-2-yl]amino]-3,3-dimethyl-1-oxobutan-2-yl]cbamate sulfate Reyataz {Sulfate} methyl((5S,10S,11S,14S)-11-benzyl-5-(tert-butyl)-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-(4-(pyridin-2-yl)benzyl)-2-oxa-4,7,8,12-tetraazahexadecan-14-yl)cbamatesulfate BMS-232632 sulfate butanoic acid, 2-[(methoxycarbonyl)amino]-3,3-dimethyl-, 2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethyl-1-oxobutyl]amino]-4-phenylbutyl]-2-[[4-(2-pyridinyl)phenyl]methyl]hydrazi de, (2S)-, sulfate (1:1) (salt) 1-(4-Biphenylyl)-4(S)-hydroxy-5(S)-2,5-bis{[N-(methoxycbonyl-)-L-tert-leucinyl]amino}-6-phenyl-2-azahexane Atazanavir sulfate RS Atazanavir sulfate CRS Methyl-[(1S,4S,5S,10S)-4-benzyl-1,10-di-tert-butyl-5-hydroxy-2,9,12-trioxo-7-(4-pyridin-2-ylbenzyl)-13-oxa-3,7,8,11-tetraazatetradec-1-yl]carbamatsulfat(salt) Atazanavir Sulphate |
| Description | Atazanavir sulfate is a sulfate salt form of atazanavir that is an highly potent HIV-1 protease inhibitor.Target: HIV-1 protease inhibitorAtazanavir sulfate is a sulfate salt form of atazanavir that is an highly potent HIV-1 protease inhibitor. It has a pharmacokinetic profile that supports once-daily dosing and has demonstrated a unique resistance profile and superior virologic potency compared with other antiretrovirals in vitro. In subjects with HIV, atazanavir (400 mg once daily) produced rapid and sustained improvements in viral load and CD4 counts in both antiretroviral-naive as well as previously treated patients when used in combination with dual nucleoside reverse transcriptase inhibitor (NRTI) treatment [1].After intravenous (iv), oral (po) and intraportal (ip) administration of ATV at a dosage of 7 mg/kg, AUCs in HL rats were 12.41, 5.24 and 8.89 microg/mLh, respectively, and were significantly higher than those in control rats (4.09, 1.70 and 3.38 microg/mLh). Despite the decrease of distribution volume (Vd(ss)), the terminal half-life (t(1/2)) in HL tended to be shorter than in control, and hepatic distribution of ATV in HL rats was 4.8-fold increases. These results suggested that the uptake of ATV into liver might counteract the decrease of Vd(ss). On the other hand, there was no significant difference in bioavailability, and the lymphatic transport to AUC showed no statistical change. In conclusion, although the protein binding rate and AUC were significantly increased, the pharmacokinetics of ATV might be tolerated in HL [2].Clinical indications: HIV-1 infection Toxicity: torsades de pointes |
|---|---|
| Related Catalog | |
| References |
| Density | 1.164g/cm3 |
|---|---|
| Boiling Point | 995.5ºC at 760 mmHg |
| Melting Point | 195.0°, or acetone; mp 198-199° (dec) |
| Molecular Formula | C38H54N6O11S |
| Molecular Weight | 802.934 |
| Flash Point | 555.8ºC |
| Exact Mass | 802.357117 |
| PSA | 254.20000 |
| LogP | 6.20320 |
| Vapour Pressure | 0mmHg at 25°C |
| Symbol |
GHS05, GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H318-H372 |
| Precautionary Statements | P260-P280-P305 + P351 + P338 + P310 |
| Target Organs | Heart, Liver |
| Hazard Codes | Xi |
| Safety Phrases | 24/25 |
| RIDADR | NONH for all modes of transport |